An exploration of the history and controversies surrounding mdma and mda

Journal of Psychoactive Drugs

Volumn 33, Issue 3, 2001, Pages 213-221

  Pentney, Alana R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ecstasy; Entactogens; MDA; MDMA

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHOSTIMULANT AGENT;

DRUG RESEARCH; MEDICAL RESEARCH; NEUROTOXICITY; POLICY; PSYCHOTHERAPY; REVIEW; UNITED STATES;

EID: 0034767580     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2001.10400568     Document Type: Article

References (55)

1. Beck, J. 1990. The public health implications of MDMA use. In: S.J. Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
2. Beck, J. & Rosenbaum, M. 1994. The Pursuit of Ecstasy: The MDMA Experience. New York: SUNY.
3. Byard, R.W.; Gilbert, J.; James, R. & Lokan, R.J. 1998. Amphetamine derivative deaths in South Australia-Is "ecstasy" the culprit? American Journal ofForensics and Medical Pathology 19: 261-65.
4. Clirnko, R.P.; Roehrich, H.; Sweeny, D.R. & Al-razi, J. 1987. Ecstasy: A review of MDMA and MDA. International Journal of Psychiatry in Medicine 16: 359-71.
5. Dar, K.J. & McBrien, ME. 1996. MDMA induced hyperthermia: Report of a fatality and review of current therapy. Intensive Care Medicine 22: 995-6.
6. De Boer, D.; Gijzels, M.J.; Bosman, l.J. & Maes, R.A.A. 1999. More data about the new psychoactive drug 2C-B. Journal of Analytical Toxicology 23: 227-8.
7. DeQuincy, T. 1995. [1821] Confessionsofan English Opium-Eater. New York: Dover Publications.
8. Dowling, G.P. 1990. Human deaths and toxic reactions attributed to MDMA and MDEA. In: S.J. Peroutka (Ed.) Ecstasy: the Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
9. Frank, R.S. 1983. The clandestine drug laboratory situation in the United States. Journal of Forensic Science 28: 18-31.
10. Greer, G.R. & Tolbert, R. 1998. A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs 30: 371-79.
11. Greer, G.R. & Tolbert, R. 1990. The therapeutic use of MDMA. In: S.J. Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
12. Grinspoon, L. & Bakalar, J.B. 1986. Can drugs be used to enhance the psychotherapeutic process? American Journal of Psychotherapy 40: 393-404.
13. Grob, C.S.; Bravo, G.L; Walsh, R.N. & Leister, MB. 1992. The MDMA-neurotoxicity controversy: Implications for clinical research with novel psychoactive drugs. Journal ofNervous and Mental Disease 180: 355-6.
14. Gunn, J.A., Gurd, MR. & Sachs, I. 1939. The action of some amines related to adrenaline: Methoxyphenylisopropylamines. Journal of Physiology 95: 485-500.
15. Hall, A.P. 1997. Hyponatraemia, water intoxication and "ecstasy". Intensive Care Medicine 23: 1289.
16. Hardman, H.F.; Haavik, C.O. & Seevers, M.H. 1973. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicology and Applied Pharmacology 25: 299-309.
17. Harrington, R.D.; Woodward, J.A.; Hooton, T.M. & Horn, J.R. 1999. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine 159: 2221-4.
18. Henry, J.A. 2000. Personal communication.
19. Hegadoren, K.M. 1995. Metabolic, Behavioral, and Neurochemical Studies of 3,4-Methylenedioxy Analogues of Amphetamine. PhD. Thesis, University of Alberta, Edmonton, Alberta, Canada.
20. Hegadoren, K.M.; Baker, G.B. & Bourin, M. 1999. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans. Neuroscience and Biobehavioral Review 23: 539-55.
21. Holden, R. & Jackson, M.A. 1996. Near fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA). Lancet 347: 1052.
22. Klassen, C.D. & Watkins, J.B. 1999. Cassaretl and Doull’s Toxicology: The Basic Science of Poisons, Fifth Ed. Companion Handbook. New York: McGraw-Hill.
23. Loman, J.; Myerson, P.G. & Myerson, A. 1941. Experimental pharmacology of post-encephalitic Parkinson's disease. Trans-American Neurology Association 67: 201-03.
24. Matthai, S.M.; Davidson, D C.; Sills, J.A. & Alexandrou, D. 1996. Cerebral oedema after ingestion of MDMA (“Ecstasy") and unrestricted intake of water. British Medical Journal 312: 1359.
25. Milosevic, A.; Agrawal, N.; Redfearn, P.J. & Mair, L.H. 1999. The occurrence of toothwear in users of ecstasy (3,4-methylenedioxymethamphetamine). Community Dentistry and Oral Epidemiology 27: 283-7.
26. Milroy, C.M. 1999. Ten years of"ecstasy" Journal of the Royal Society of Medicine 92: 68-72.
27. Molliver, DC. & Molliver, ME. 1990. Anatomic evidence for a neurotoxic effect of fenfluramine upon serotonergic projections in the rat. Brain Research 511: 165-68.
28. Naranjo, C.; Shulgin, A T. & Sargent, T. 1967. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Medicina et Pharmacologia Experimentalis 17: 359-64.
29. Nichols, D.E. 2000. Personal communication.
30. Nichols, D.E. 1986. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. Journal of Psychoactive Drugs 18: 305-13.
31. Nichols, D.E.; Hoffman, A.J.; Oberlender, R.A.; Jacob, P. & Shulgin, A.T. 1986. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class. Journal ofMedicinal Chemistry 29: 2009-15.
32. Parr, M.J.A.; Low, H.M. & Botterill, P. 1997. Hyponatremia and death after "ecstasy" ingestion. Medical Journal ofAustralia 166: 136-7.
33. Pellerin, C. 1998. Trips: How Hallucinogens Work in Your Brain. New York: Seven Stories Press.
34. Peroutka S.J. 1990a. Preface. In: S.J. Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
35. Peroutka, S.J. 1990b. Recreational useofMDMA. In: S.J. Peroutka (Ed.) Ecstasy: the Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
36. Plotinus, P. 1991. The Enneads. Translated by: Stephen MacKenna; introduction by: John Dillon. New York: Penguin Books.
37. Price, L.H.; Ricaurte, G.A.; Krystal, J.H. & Henninger, G.R. 1989. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxyamphetamine (MDMA) users. Archives of General Psychiatry 46: 20-22.
38. Ramsey, J. (LondonToxicology Group). 2000. Personal communication.
39. Riedlinger, J.E. 1985. The scheduling of MDMA: A pharmacist's perspective. Journal of Psychoactive Drugs 17: 167-71.
40. Riedlinger, T.J. & Riedlinger, J.E. 1994. Psychedelic and entactogenic drugs in the treatment of depression. Journal of Psychoactive Drugs 26: 41-55.
41. Rochester, JA. & Kirchner, J.T. 1998. Ecstasy (3,4-methylenedioxy-rnethamp^^^ra): History, neurochemistry, and toxicology. Journal of the American Board of Family Practitioners 12: 137-42.
42. Sferios, E. 1999. Laboratory analysis program reveals DXM tablets sold as “ecstasy " Bulletin of the Multidisciplinary Association for Psychedelic Studies 9 (4): 47-8.
43. Shewan, D.; Dalgarno, P. & King, L.A. 1996. Such as ketamine. British Medical Journal 313: 424.
44. Shulgin, AT. 2000. Personal communication.
45. Shulgin, AT. 1990. History of MDMA. In: S. J. Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA. Boston, Massachusetts: Kluwer Academic.
46. Shulgin, AT. 1986. The background and chemistry of MDMA. Journal ofPsychoactive Drugs 18: 291-304.
47. Shulgin, A.T. 1978. Psychomimetic drugs: Structure-activity relationships. In: L.L. Iverson; S.D. Iverson & S.H. Snyder (Eds.) Handbook of Psychopharmacology. New York: Plenum Press.
48. Shulgin, A.T. & Nichols, D.E. 1978. Characterization of three new psychomimetics. In: Stillman and Willette (Eds.) The Psychopharmacology of Hallucinogens. New York: Pergamon Press.
49. Shulgin, A. & Shulgin, A. 1997. TIHKAL: The Continuation. Berkeley, California: Transform Press.
50. Shulgin, A. & Shulgin, A. 1990. PIHKAL: A Chemical Love Story. Berkeley, CA: Transform Press.
51. Sprague, J.E.; Everman, S.L. & Nichols, D.E. 1998. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19: 427-42.
52. Vollenweider, F.X.; Remensberger, S.; Hell, D. & Geyer, M.A. 1999. Opposite effects of 3,4-methylenedioxyamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology 143: 365-372.
53. White, J.M.; Bochner, F. & Irvine R.J. 1997. The agony of “ecstasy." Medical Journal of Australia 166: 117-18.
54. Winstock, A.R. & King, L.A. 1996. Tablets often contain substances in addition to, or instead of, ecstasy. British Medical Journal 313: 423-4.
55. Wu, D.; Otton, S.V.; lnaba, T.; Kalow, W. & Sellers, E M. 1997. Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology 53: 1605-12.